---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-028453"
form_type: "8-K"
ticker: "PALI"
cik: "0001357459"
company_name: "PALISADE BIO, INC."
filed_at: "2022-10-14T23:59:59+00:00"
generated_at: "2026-06-23T03:30:19.488663+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Palisade Bio CEO Thomas Hallam resigns; CFO JD Finley appointed interim CEO

## Summary
- CEO Thomas Hallam resigned effective Oct 11, 2022; separation agreement includes $530,000 paid over 12 months, COBRA, accelerated vesting.
- JD Finley, current CFO, appointed interim CEO effective Oct 10; will continue as CFO.
- Company will not present at American College of Surgeons Clinical Congress 2022 to focus on internal reorganization.
- Dr. Hallam's resignation not due to any disagreement on operations, policies, or practices.

## SEC filing metadata
- accession: 0001493152-22-028453
- form_type: 8-K
- ticker: PALI
- cik: 0001357459
- company_name: PALISADE BIO, INC.
- filed_at: 2022-10-14T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357459/000149315222028453/0001493152-22-028453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357459/000149315222028453/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-028453
- JSON: https://secwatch.observer/filing/0001493152-22-028453.json
- Plain text: https://secwatch.observer/filing/0001493152-22-028453.txt

## Key facts
- Executive change
  J.D. Finley was appointed as Chief Executive Officer (principal executive officer), interim; continuing as Chief Financial Officer at PALISADE BIO, INC..
  - Action: appointed
  - Role: Chief Executive Officer (principal executive officer), interim; continuing as Chief Financial Officer
  source text: As of the Effective Date, J.D. Finley, the Company’s current Chief Financial Officer, was appointed by the Board to serve as the Company’s Chief Executive Officer (principal executive officer), on an interim basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357459/000149315222028453/0001493152-22-028453-index.htm
- Executive change
  Thomas Hallam resigned as Chief Executive Officer and member of the Board of Directors at PALISADE BIO, INC..
  - Action: resigned
  - Role: Chief Executive Officer and member of the Board of Directors
  source text: Effective October 11, 2022 (the “Effective Date”), Thomas Hallam, Ph.D., the Chief Executive Officer and a member of the Board of Directors (the “Board”) of Palisade Bio, Inc. and its wholly owned subsidiary, Leading Biosciences, Inc. (collectively the “Company”) resigned as both Chief Executive Officer and as a member of the Board, of both entities, to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357459/000149315222028453/0001493152-22-028453-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.